Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

SRZN vs ATYR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ATYR Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 2–5 Matrix Metrics)

ATYR Overall Winner 6-Pillar Tally: SRZN 2 – 3 ATYR (1 Tie) Matrix Metrics: SRZN 5 – 2 ATYR

As of Nov 17, 2026, aTyr Pharma, Inc. (ATYR) is the stronger overall head-to-head candidate over Surrozen, Inc. Common (SRZN) in the Tradestie Institutional Equity Comparison Engine, winning 2–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). SRZN carries a Unified Composite Score of 33.2/100 (SELL) at $30.16 (N/M Forward P/E, -485.4% operating margin), whereas ATYR carries 34.3/100 (SELL) at $4.96 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: ATYR earns the overall head-to-head edge with a stronger Unified Composite Score (34.3/100 SELL vs. SRZN 33.2/100 SELL) and -9.67β · 13806% Vol risk profile, whereas SRZN leads top-line expansion (+408.6% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Defensive Composite Rating Caution: Although ATYR compares more favorably head-to-head, both SRZN (33.2/100 SELL) and ATYR (34.3/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SRZN vs ATYR
SRZN NASDAQ
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$30.16
-6.68% 1D
Market Cap $602.5M
TTM Revenue $11M
Forward P/E N/M
Beta / 30D Vol 1.28β · 70% Vol
Unified Composite Score
33.2 / 100 SELL
Tech 50.0 Fund 34.0 Flow 65.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (10.9% over 20 days), RSI 53
RSI-14: 53.1 · SMA20: $29.76 · SMA50: $26.28
ATYR NASDAQ Head-to-Head Winner
aTyr Pharma, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$4.96
-5.34% 1D
Market Cap $15.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -9.67β · 13806% Vol
Unified Composite Score
34.3 / 100 SELL
Tech 50.0 Fund 36.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (391.4% over 20 days), RSI 58
RSI-14: 57.6 · SMA20: $4.36 · SMA50: $1.92

6-Pillar Scorecard Institutional Category Breakdown (SRZN 2 – 3 ATYR)

Columns: Metric · SRZN · ATYR
1. Valuation Multiples SRZN
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 48.3x N/M
2. Growth & Scale SRZN
Revenue Growth (YoY) +408.6% +0.0%
Earnings Growth (YoY) -37.0% +0.0%
TTM Revenue (USD) $11M N/A
Market Cap $602.5M $15.6M
3. Profitability & Quality ATYR
Gross Margin N/A N/A
Operating Margin -485.4% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -62.8% -93.7%
4. Balance Sheet & Cash Flow ATYR
Cash Generation (TTM) -$31M N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $95M Net Cash $4.9M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ATYR
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 72.0% (5th %ile) 154.5% (36th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SRZN (5) vs ATYR (2)
Institutional Metric SRZN ATYR Criterion Row Edge
Market Capitalization
Scale
$602.5M $15.6M Larger Scale SRZN
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+408.6% +0.0% Higher Growth SRZN
Operating Margin (TTM)
Profitability
-485.4% 0.0% Higher Margin ATYR
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-62.8% -93.7% Higher ROE SRZN
52-Week Range Position
Momentum
70% ($12–$38) 62% ($0–$8) Stronger Trend SRZN
Beta / 30D Volatility
Risk Regime
1.28β · 70% Vol -9.67β · 13806% Vol Lower Realized Risk SRZN
Unified Institutional Score
Composite Signal
33.2 / 100 (SELL) 34.3 / 100 (SELL) Higher Composite ATYR
Trailing 12M Revenue (USD)
Operating Scale
$11M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 48.3x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$31M ($95M Net Cash) N/A ($4.9M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ATYR +2762.25 pp
SRZN: +26.51% · ATYR: +2788.76%
3M Horizon ATYR +805.32 pp
SRZN: +25.61% · ATYR: +830.93%
6M Horizon ATYR +908.97 pp
SRZN: +17.95% · ATYR: +926.92%
1Y Horizon ATYR +426.34 pp
SRZN: +132.36% · ATYR: +558.7%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SRZN Revenue ATYR Revenue SRZN Op. Margin ATYR Op. Margin Margin Leader
FY2019 N/A $0M N/A -5445.0% ATYR
FY2020 N/A $10M N/A -152.2% ATYR
FY2022 $10M $10M -354.7% -446.8% SRZN
FY2023 N/A $0M N/A -15557.8% ATYR
FY2024 $10M $0M -239.7% -28899.6% SRZN
FY2025 $0M $0M -1210.6% -40856.3% SRZN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SRZN CONSOLIDATION
38d in phase · OBV NEUTRAL
Current IV 72.0%
IV Percentile 5th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact SRZN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ATYR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 154.5%
IV Percentile 36th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ATYR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SRZN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $602.5M market capitalization and -485.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ATYR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $15.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SRZN vs ATYR Key Questions & Quantitative Answers

As of Nov 17, 2026, aTyr Pharma, Inc. (ATYR) is the stronger overall head-to-head candidate over Surrozen, Inc. Common (SRZN) in the Tradestie Institutional Equity Comparison Engine, winning 2–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). SRZN carries a Unified Composite Score of 33.2/100 (SELL) at $30.16 (N/M Forward P/E, -485.4% operating margin), whereas ATYR carries 34.3/100 (SELL) at $4.96 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: ATYR earns the overall head-to-head edge with a stronger Unified Composite Score (34.3/100 SELL vs. SRZN 33.2/100 SELL) and -9.67β · 13806% Vol risk profile, whereas SRZN leads top-line expansion (+408.6% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Defensive Composite Rating Caution: Although ATYR compares more favorably head-to-head, both SRZN (33.2/100 SELL) and ATYR (34.3/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

SRZN leads the Growth & Scale pillar: SRZN posts +408.6% YoY revenue growth and -37.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, -485.4% operating margin), compared with ATYR at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 6-period historical trajectory (FY2019 to FY2025), SRZN cumulative revenue shifted +0.0% while ATYR shifted +0.0%. In operating R&D and SG&A reinvestment, SRZN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ATYR.

SRZN screens cheaper on headline valuation multiples. SRZN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 48.3x EV/Revenue (unreported FCF margin), whereas ATYR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SRZN (-62.8% ROE) versus ATYR (-93.7% ROE) capital efficiency.

In options market volatility and institutional positioning, SRZN carries 72.0% implied volatility (5th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.28β · 70% Vol realized risk). By comparison, ATYR carries 154.5% implied volatility (36th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-9.67β · 13806% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.